We herein present evidence concerning the impact of the immunohistochemical expression of key Hippo transducers and their regulators, namely AMP-activated protein kinase (AMPK), Stearoyl-CoA-desaturase 1 (SCD1), and HMG-CoA reductase (HMGCR), on the pCR rate of 65 Her2+ BC patients receiving neoadjuvant trastuzumab-based therapy. Here, HMGCR is linked to breast cancer.